Compare Novartis AG (NVS) vs Raytheon Technologies Corp (RTX) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

RTX trades at $197.55, down 1.61% today, but maintains a bullish technical outlook with strong support near $197 and resistance at $200. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.75. Revenue growth accelerated to $88.6 billion in 2025, with net income reaching $6.73 billion. Recent contract wins include a $515 million U.S. Navy radar award announced June 3, 2026.

Outlook remains positive with 65% analyst buy ratings and a $235.33 price target implying 19% upside. Key risks include execution challenges in scaling munitions production and dependence on defense budgets. Strong cash flow generation and expanding margins support continued dividend payments, with the next $0.73 dividend payable September 3, 2026.